GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reissued by Goldman Sachs Group, Inc. (The) in a research report issued on Tuesday, October 17th. They currently have a GBX 1,900 ($24.99) price target on the stock. Goldman Sachs Group, Inc. (The)’s target price suggests a potential upside of 39.65% from the stock’s previous close.
A number of other equities research analysts also recently weighed in on the company. Barclays PLC reaffirmed an “equal weight” rating and issued a GBX 1,550 ($20.39) target price on shares of GlaxoSmithKline plc in a report on Monday, July 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 1,900 ($24.99) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Deutsche Bank AG reaffirmed a “hold” rating and set a GBX 1,610 ($21.18) target price on shares of GlaxoSmithKline plc in a research report on Wednesday, October 11th. Liberum Capital reaffirmed a “buy” rating and set a GBX 1,900 ($24.99) target price on shares of GlaxoSmithKline plc in a research report on Wednesday, August 30th. Finally, J P Morgan Chase & Co lowered their price objective on GlaxoSmithKline plc from GBX 1,750 ($23.02) to GBX 1,570 ($20.65) and set a “neutral” rating for the company in a research report on Wednesday, September 13th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline plc presently has a consensus rating of “Hold” and an average price target of GBX 1,612.25 ($21.21).
GlaxoSmithKline plc (LON:GSK) traded down GBX 0.50 ($0.01) during trading hours on Tuesday, reaching GBX 1,360.50 ($17.89). The company’s stock had a trading volume of 6,536,227 shares.
GlaxoSmithKline plc (LON:GSK) last issued its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%.
In other GlaxoSmithKline plc news, insider Simon Dingemans purchased 1,076 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were acquired at an average cost of GBX 1,527 ($20.08) per share, for a total transaction of £16,430.52 ($21,610.57). Also, insider Urs Rohner purchased 473 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). In the last quarter, insiders have bought 1,574 shares of company stock worth $2,398,888.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with our FREE daily email newsletter.